FREDERICK, Md., Oct. 23 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that TSS Medical, Tecnica Scientifica Service, has signed an agreement for the distribution of ActiPatch(TM) in Italy. The initial order shipped on October 10th.
TSS Medical joins the growing list of international distributors for ActiPatch Therapy. BioElectronics has signed agreements in place and shipping has commenced to Germany, Kuwait, Singapore, Malaysia, Turkey, Columbia, Canada, the United Kingdom, Panama, Canada and Mexico. The Company expects to ship product to both Saudi Arabia and Korea by month’s end.
“We are pleased to have aligned BioElectronics Corporation with TSS Medical to bring the benefits of ActiPatch healing to the people of Italy. We look forward to a mutually beneficial relationship for years to come,” said Andrew Whelan of BioElectronics.
“TSS Medical will make an official presentation of ActiPatch to the Italian market at the ESRA Congress in Salerno City later this month. We are very excited about the market potential for this innovative, drug-free therapy. Our 40 sales representatives cover 80% of the Italian market and we expect to have significant sales revenue from ActiPatch products,” said Mr. Alessio Petricca of TSS Medical.
About TSS Medical:
TSS Medical was established in 1998, employs 35 sales agents and has annual revenue in excess of 5 million Euros. TSS is headquartered in Torino, Italy and maintains ISO 9000 and TUV certification.
For more information visit http://www.tssmedical.com
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation,
+1-301-874-4890, Fax: +1-301-874-6935, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com/
http://www.tssmedical.com/
